Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Akebia Therapeutics 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142 USA

www.akebia.com Employees: 167 P: 617-871-2098 F: 617-871-2099

Description:

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 399,271
Enterprise Value, $K 391,021
Shares Outstanding, K 218,181
Annual Sales, $ 194,620 K
Annual Net Income, $ -51,930 K
Last Quarter Sales, $ 37,430 K
Last Quarter Net Income, $ -20,040 K
EBIT, $ -35,470 K
EBITDA, $ 2,160 K
60-Month Beta 0.70
% of Insider Shareholders 4.10%
% of Institutional Shareholders 33.92%
Float, K 209,236
% Float 95.90%
Short Volume Ratio 0.55

Growth:

1-Year Return 52.50%
3-Year Return -27.67%
5-Year Return -71.93%
5-Year Revenue Growth -6.32%
5-Year Earnings Growth 88.52%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.10 on 11/07/24
Next Earnings Date N/A
Earnings Per Share ttm -0.23
EPS Growth vs. Prev Qtr -150.00%
EPS Growth vs. Prev Year -25.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

AKBA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -20.57%
Profit Margin % -26.68%
Debt/Equity -0.76
Price/Sales 2.05
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.24
Interest Coverage -7.61
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar